Introduction
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for a variety of malignant and nonmalignant hematological disorders. 1 Despite remarkable advances in the field of HSCT, the morbidity and mortality associated with this modality remain significant. The decision to recommend HSCT is not simply dependent on patient diagnosis, instead it is a complex process intricately dependent on a number of variables including patient age, performance status, medical comorbidities, family support structure, socioeconomic viability and motivation to participate in self-care, to name a few.
Assimilating the available data to reach a safe and rational conclusion regarding a patient's transplant eligibility, not only requires an experienced transplant physician, but it is also critically dependent on the services of experienced transplant nurses, mid-level providers, specialized social workers, insurance experts and transplant coordinators. Despite the immense complexity of the process of selecting appropriate candidates for SCT, surprisingly little has been published addressing this scenario. 2 This review aims to provide an overview of the complex process of transplant evaluation. However, it is important to point out that no formal guidelines exist to conduct pre-HSCT evaluation; and hence certain recommendations in this review reflect our 'biases' and are not necessarily evidence based.
Initial transplant evaluation visit
The first visit for transplant evaluation is not only a stressful experience for the patient and his/her relatives, but it also requires him/her to learn and comprehend the complex process leading up to HSCT, its risks, benefits and alternative treatment options. Scheduling ample time with the transplant physician and coordinators is mandatory for a meaningful transplant consultation.
Patient education handouts and web resources
Many patients referred for transplantation undertake some kind of research before their initial transplant evaluation visit. A large proportion of such patients rely exclusively on different websites, and depending on the quality of web resource accessed, these patients can be either quite knowledgeable or completely misinformed about the process of HSCT. An alarming proportion of patients also visit a variety of internet chat rooms, which are described quite accurately by Blume and Amylon 2 as 'goldmines for misinformation'. Directing internet savvy patients to reliable web resources, 3 and providing patients with authentic, easy to read, patient education materials before first visit (or at least during initial consultation) is often very helpful. Such reading materials not only provide basic information about the process, rationale, logistics, complications and outcomes of transplantation, but also promote various intelligent questions.
Identifying communication barriers and goals of initial consultation
The importance of communicating with the patients in easily understandable (lay) language cannot be overemphasized. The majority of patients have never heard terms such as allogeneic, autologous, reduced-intensity, GVHD. To facilitate effective communication, it is imperative to avoid medical jargon. 2 For example, many patients confuse 'stem cells' with 'embryonic stem cells', others assume that the source of cord blood for transplantation is 'aborted fetuses'. It is the job of the transplant physician to identify and address such barriers and misconceptions. In our opinion the aim of the initial encounter is to educate the patient about why transplantation is indicated, what are the non-transplant treatment options and what are the associated risks/benefits. Expecting the patient to reach a decision about whether he or she wants to proceed with HSCT during the first visit is not a reasonable aim. This decision is best left for a later visit, when the patient has had an opportunity to consider the pros and cons. It is also vital to educate the patient about various stem cell sources (BM, peripheral blood or cord blood units), transplant types (autologous, allogeneic, myeloablative, reduced intensity), donor sources (autologous, sibling and unrelated) and to explain why a given modality is preferred for an individual patient.
Important topics to discuss during consultation
Although it is not possible to discuss all the issues that might need to be addressed during a patient's transplant evaluation, we highlight a few important points. Most patients have limited understanding of how stem cells are procured. For autologous HSCT candidates, it is important to give a brief description of how stem cells are harvested or mobilized and cryopreserved. It is prudent to mention the possibility of stem cell mobilization failure in select highrisk patients (with history of lenalidomide use, multiple lines of chemotherapy, radiation exposure or Hodgkin's disease). Allogeneic transplant candidates often voice concerns about donor safety with stem cell donation (especially in cases of related donors), and must be reassured that life-threatening complications in HSCT donors are exceedingly rare. 4, 5 Perhaps the most difficult part of HSCT consultation is educating the patient about possible complications of transplantation (Table 1) . Providing patients with an accurate description of expected complications, while not scaring them away from a potentially curative treatment option, is an art learned only with practice and time.
Estimates of TRM (depending on the type of transplant and other confounders) range from 5 to 40%; hence, it is critical to ensure that patients understand that risks associated with this procedure are real (and so are the benefits).
2 Approximately 5-10% of transplant recipients require artificial life support within the first 100 days after HSCT, underscoring the need for addressing patient's wishes regarding limits of care, and the Durable Power of Attorney for Health Care. Studies have shown that failing to address advance care planning is associated with poor transplant outcomes. 6 In transplant candidates, especially in younger patients, the high risk of permanent infertility is a major issue. Although many transplant survivors retain or recover their reproductive potential, it is currently not possible to accurately identify such patients before transplantation. Information regarding sperm, egg or embryo cryopreservation (despite its limited success) must be made available to interested patients. [7] [8] [9] [10] A sizable number of transplant candidates represent many ethnic or religious minorities. It is important to identify and respect cultural or religious values of this unique population while planning their transplant care. For instance, in the event of a Jehovah's Witness undergoing transplant evaluation, addressing restrictions on blood product administration is critical. Referral of such patients to centers experienced in so-called 'bloodless' transplants should be considered. 11, 12 Dietary restrictions of Jewish (Kosher food), Muslim (Halal meal) or Hindu (restriction on beef) patients should be identified during hospital admissions. Finally, for allogeneic transplant candidates the process of identifying potential (related or unrelated volunteer or cord blood) donors, rationale of HLA typing and probabilities of finding a sibling or unrelated donor need special attention.
Evaluating disease and remission status
The histological type and remission status of the underlying disorder are the key determinants of whether HSCT is indicated in any given patient and which type of transplant offers the best risk/benefit ratio. Table 2 summarizes HSCT indications in various adult hematological disorders. Detailed discussion of individual disorders is beyond the scope of this review. Assessment of disease remission status with imaging studies, BM biopsy and so on, before transplantation has important ramifications. Autologous (and perhaps allogeneic) transplantation in patients with chemotherapy-refractory lymphomas offer little prospect of cure. [13] [14] [15] Similarly, outcomes of leukemia patients undergoing allografting while in complete remission are clearly superior to those with refractory disease. [16] [17] [18] In patients seeking multiple opinions, it is not uncommon to find different transplant centers giving divergent recommendations about similar clinical scenarios. 19 Local preferences, personal biases and lack of trial data in areas of controversy are likely to be responsible for such variations.
The expected cure rate with transplant is the single most important question in the minds of patients. A candid discussion with the patients about their long-term survival probabilities is challenging, but absolutely essential. It is better to provide a range of expected survival rates rather than quoting absolute numbers. Despite such candid discussions, huge disparities exist between physician estimates and patient perceptions about transplantation outcomes. Such disparities are more apparent in patients with advanced malignancies. Lee et al. 20 showed that for transplants conducted for high-risk malignancies, the physicians' estimated cure rates (31%), differed markedly from patient perceived estimates (80%). Although this study highlights the need for better physician-patient communication, it also sheds light on the psychology of a desperate patient trying to think and focus on the 'positive'. 2 
Evaluating physiological status
In addition to histological diagnosis, transplantation outcomes are also dependent on the presence or absence of medical comorbidities. Detailed history, physical examination and clinical testing to assess performance and physiological status have paramount importance in safer application of HSCT (Table 3) . Table 4 lists a set of common parameters used to evaluate patient eligibility for HSCT. However, it should be emphasized that these parameters do not represent absolute contraindications for transplantation, but merely serve as (soft) guidelines for optimal patient selection.
Age and performance status
With advances in supportive care and transplant conditioning regimens, the dogma of not offering HSCT to older patients no longer holds true. [21] [22] [23] [24] Autologous and reduced intensity conditioning (RIC) allogeneic HSCT can now be safely performed in patients as old as 75 years. While selecting optimal transplant candidates it is important to consider patient's physiological age based on coexisting comorbidities, rather than simply considering their chronological age.
2 A robust 65 years old person with no comorbidities is likely to tolerate autologous or RIC transplantation better than a 55-year-old candidate with compromised organ function. However, because old age is associated with a number of comorbidities, the importance of rigorous pre-transplant testing in the elderly patient population is paramount.
An ideal transplant candidate should be in good to excellent physical and physiological condition at the time of transplantation. Karnofsky performance status (KPS) score is a useful tool for assessing functional status. In our opinion, for patients undergoing autologous or RIC allogeneic transplantation, a KPS score of X70, and for those undergoing myeloablative allogeneic HSCT, a KPS score of X70-80 should ideally be present. However, no magical KPS score cutoff exists to include or exclude patients with 100% reliability. It is also important to realize that assignment of a particular KPS score to any given patient is a subjective assessment of the treating oncologist and hence is not always accurate.
Pulmonary evaluation
Transplant recipients can develop a variety of post-HSCT pulmonary complications, including conditioning regimenrelated lung toxicity (TBI, BU, carmustine), pulmonary GVHD, alveolar hemorrhage, idiopathic pneumonia syndrome, transfusion-related acute lung injury, infectious complications, and so on. [25] [26] [27] Pulmonary function tests (PFTs) before HSCT can help identify patients at increased risk of developing post transplant pulmonary complications. Detection of abnormal diffusion capacity for carbon monoxide and alveolar-arterial oxygen gradient on PFT are independent predictors of the need for mechanical ventilation and mortality post-HSCT. 28 Moreover PFT can also predict the risk of late decline in pulmonary function. For example, patients with a low pre-transplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second who develop chronic GVHD are seven times more likely to develop a late decline in pulmonary function. 29 PFT might also help tailor transplant conditioning regimens. An interesting National Institute of Health study reported survival benefit with limiting the dose of TBI delivered to the lungs (9 Gy, instead of 13.6 Gy), in patients with combined forced expiratory volume in the first second and diffusion capacity for carbon monoxide deficits.
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Advice regarding smoking cessation is often underemphasized during pre-transplant counseling sessions. Smoking increases the TRM from pulmonary causes fivefold. 31 Center for International Blood and Marrow Transplant Research data also suggest increased TRM and inferior overall survival in heavy smokers, 32 underscoring the importance of smoking cessation counseling during pre-transplant evaluation. 
Cardiac evaluation
Advanced age, prior anthracycline use, and CY-based conditioning regimens are potential risk factors for post transplant cardiac complications. In practice, however, lifethreatening cardiotoxicity after HSCT is relatively uncommon. In a study involving 2821 patients undergoing HSCT at the University of Minnesota, the rate of major or fatal post transplant cardiotoxicity was less than 1%. 33 Some, 34 but not all, studies have suggested an association between low pre-transplant left ventricular ejection fraction and risk of developing post-HSCT cardiotoxicity. [35] [36] [37] [38] Left ventricular ejection fraction of X45-50%, assessed either by two-dimensional echocardiography or multigated acquisition scan, is arbitrarily chosen as an HSCT eligibility criterion by most transplant centers. In hypertensive patients, adequate control of blood pressure before transplantation is extremely important, especially in the setting of allogeneic HSCT, as post transplant immunosuppressive medications (CYA, tacrolimus) can exacerbate hypertension.
Routine 12-lead electrocardiogram must be performed in all potential HSCT candidates, as it remains a source of useful prognostic information. Presence of QT-interval prolongation or QT-interval dispersion (that is, the difference between the maximum and minimum QT intervals) on routine electrocardiogram monitoring is an independent predictor of the risk of developing acute heart failure post transplantation. 39, 40 Pre-transplant electrocardiogram should also be carefully reviewed to ensure absence of significant conduction or rhythm abnormalities. Stem cell infusion and physiological stress of the immediate post transplant period predisposes the patients to developing supraventricular tachyarrhythmias (or less commonly ventricular arrhythmias). Older patients are especially at risk of developing post transplant supraventricular tachyarrhythmias. 41 No conclusive data suggest that more extensive cardiac evaluation with modalities such as cardiac CAT scans, myocardial perfusion scans, cardiac stress testing or cardiac biomarker determination can improve the ability to predict the risk of post transplantation cardiac complications and are not routinely performed.
Hepatic and nutritional evaluation
Assessment of liver function (serum bilirubin concentration, transaminases and albumin level) is routinely performed during pre-transplant evaluation. Baseline elevation of serum transaminases and alkaline phosphatase is a risk factor for developing veno-occlusive disease of the liver after transplantation. 42 In transplant candidates with elevated liver enzymes detailed workup, and preferably consultation with an experience hepatologist must be sought to identify any reversible cause of liver function abnormalities. In patients with hematological malignancies, liver function abnormalities secondary to transfusionrelated iron overload are not uncommon. Determination of serum ferritin, iron profile, hepatic magnetic resonance imaging and/or liver biopsy can help identify such patients. Appropriate chelation therapy can lead to improvement in hepatic function.
Although serum ferritin levels are not routinely determined before HSCT, mounting evidence suggests association of elevated baseline ferritin level with increased TRM, risk of veno-occlusive disease and inferior disease-free and overall survival. [43] [44] [45] [46] [47] Referral of patients with anorexia, cachexia, malnutrition or morbid obesity to an experience dietician should be a part of routine transplant workup. Obesity alone should not be viewed as a contraindication to HSCT. In fact, overweight and obese patients experience lower mortality compared to underweight patients. 48 Renal function evaluation Exposure of transplant recipients to a number of potentially nephrotoxic medications (MTX, CYA, tacrolimus, vancomycin, aminoglycosides, acyclovir, amphotericin and so on) highlights the need for an adequate renal reserve. Baseline serum creatinine value of p1.5 mg/100 mL and a creatinine clearance above 60 mL/min before transplantation are highly desirable. In patients with an elevated serum creatinine, appropriate evaluation to identify reversible causes of renal insufficiency should be performed. Low glomerular filtration rate is an independent risk factor for developing late post-HSCT chronic renal disease, 49 whereas both low glomerular filtration rate and high serum creatinine before transplantation are risk factors for acute renal failure after HSCT. 50 While evaluating patients with borderline renal function, the risk/benefit ratio of transplantation must be carefully considered, because these patients are at increased risk of renal complications and perhaps hemodialysis after transplantation, which carries an extremely poor prognosis. 51 It is important to remember that patients with multiple myeloma and compromised renal function, undergoing high-dose therapy with melphalan and autologous HSCT, are generally expected to have favorable outcomes. [52] [53] [54] However, in multiple myeloma patients with compromised renal function, our bias is to dose reduce melphalan from 200 to 140 mg/m 2 at the time of high-dose therapy.
Viral hepatitis screening
All patients undergoing HSCT evaluation must be screened for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV). Screening for non-B and non-C hepatitis viruses is not routinely performed. Infection with HBV or HCV is by no means an 'absolute' contraindication for HSCT; however, these patients are at increased risk of post transplant viral reactivation, veno-occlusive disease, liver cirrhosis and even fulminant hepatic failure, and this fact must be kept in mind during their post-HSCT follow-up. 55 Patients with a history of resolved HBV infection before transplant (hepatitis B core Ab-positive, hepatitis B surface antigen-negative), who develop extensive chronic GVHD post transplant are seven times more likely to develop hepatitis B reactivation, 56 highlighting the need to identify at risk patients before HSCT. 57 A study from MD Anderson Cancer Center, has shown a negative impact of HCV infection on overall survival and non-relapse mortality after allogeneic transplantation, even in patients with normal liver function at baseline. 58 Decisions regarding eligibility of HBV-and HCV-infected patients for HSCT, and whether to use prophylactic or preemptive therapy (for example, famciclovir or lamivudine) for HBV carriers are best made in consultation with an experienced hepatologist.
HIV screening
All patients undergoing transplant evaluation are screened for HIV infection. In patients with a known history of HIV infection and/or AIDS, HIV viral load and absolute CD4 count must also be determined. With the development of highly active antiretroviral therapy, the last decade has witnessed an increasing number of HIV-positive patients successfully undergoing HSCT. However, the importance of appropriate patient selection cannot be overemphasized. Patients with a history of noncompliance with highly active antiretroviral therapy or uncontrolled viral loads are perhaps not suitable candidates for HSCT. The type of transplant procedure also deserves consideration. Autologous transplantation in HIV-positive patients with a CD4 count 4100 per mm 3 and an undetectable or low viral load (o10 000 copies per mL) by reverse transcriptase-PCR is well tolerated and is not associated with unusually high morbidity or mortality. [59] [60] [61] [62] Data for allografting in the HIV-positive population are limited. A Center for International Blood and Marrow Transplant Research study reported poor outcomes with myeloablative conditioning in HIV-positive patients, 63 but limited data have suggested feasibility of allografting in HIV-positive patients after RIC.
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Miscellaneous infections Profound immunosuppression in the post transplant period necessitates careful evaluation of the patients to assess the risk of infectious complications. Obtaining a history about sexual orientation, history of unprotected sexual intercourse, needle sharing, remote blood transfusions, travel history and so on can help direct the infectious disease screening workup. 66 All HSCT recipients should be tested for the presence of anti-CMV IgG Abs to determine the risk of primary CMV infection or reactivation after HSCT. All CMV seronegative recipients undergoing autologous transplantation or receiving allografts from seronegative donors must be administered CMV-negative blood products. EBV serologies can help assess allogeneic transplant candidate's risk of developing EBV-related post transplant lymphoproliferative disorders. The risk is highest in EBV seropositive patients receiving allografts from seronegative donors, and in those undergoing T-cell-depleted allogeneic transplantation. 67 Testing for serum anti-herpes simplex virus IgG and anti-VZV IgG is also routinely performed in all patients, to help estimate the risk of primary infection or viral reactivation post transplantation. Patients with history of invasive aspergillosis are at increased risk of invasive aspergillosis and mortality after HSCT. This risk is especially high in patients receiving o1 month of antibiotic therapy for invasive aspergillosis and those with persistent radiographic abnormalities at the time of transplantation. 68 It is our practice to provide antifungal prophylaxis with voriconazole in transplant candidates with history of invasive aspergillosis. Meticulous attention to the patient's infection history and appropriate investigations to rule out any active infection at the time of transplantation are of vital significance.
Dental evaluation
Pre-transplant dental evaluation and necessary surgical intervention can eliminate potential sites of infection and trauma. 69 Dental evaluation and extraction of teeth with advanced periodontitis has been advocated (and in fact required by many insurance carriers) before HSCT to prevent septicemia in transplant recipients. However, no study to date has conclusively shown a relationship between radiographic periodontal status and septicemia and/or mortality after transplant. 70 
Determination of comorbidity index
The daunting challenge of transplant evaluation is to use the information collected by investigations described in the preceding sections to accurately predict post transplantation outcomes. A number of scoring systems (Charlson Comorbidity Index, Multidimensional Assessment for Cancer in the Elderly Score, Cumulative Illness Rating Scale-Geriatric) have been used with limited success to predict HSCT outcomes. A recently described scoring system, hematopoietic cell transplantation-specific comorbidity index (HCT-CI), 71 (which has been validated in predicting outcomes of myeloablative and RIC HSCT) has rapidly gained acceptance in the transplant community (Table 5 ). Using this model, patients undergoing myeloablative transplantation, with a low HCT-CI (0-2), have been shown to experience lower non-relapse mortality (14-19%) compared to those with an HCT-CI of 3 or more (40-41%). On the basis of these results in clinical practice, it might be suitable to offer RIC transplantation to a younger patient (o55-60 years) with high HCT-CI (X3) to mitigate the otherwise unacceptably high non-relapse mortality (B40%) after myeloablative allogeneic HSCT. This approach (although not supported by prospective studies) is gaining widespread acceptance in the transplant community. In patients undergoing autologous HSCT, Psychosocial, psychological, financial and caregiver considerations Assessment of the patient's psychological health before transplantation cannot be overlooked. It is imperative to recognize and address patient concerns, depression or psychosocial instability before committing them to a lifechanging event such as transplantation. 73, 74 History of noncompliance and lack of motivation must raise red flags, as subjecting these patients to transplantation often proves to be a recipe for disaster. We recommend strongly against offering HSCT to patients actively involved in alcohol or substance abuse. The transplant candidate's social support structure should be carefully analyzed, as patients with family conflicts or those with poor caregiver structure have been shown to have poor outcomes and inferior quality of life. 75 Undergoing transplantation generally means being off work for months post-HSCT, which naturally produces a heavy financial and social strain on the patient and their families. 76 Consultation with transplant social workers to ensure insurance coverage of transplantation, arrangements for temporary disability for those in need, providing assistance with childcare, transportation, lodging and so on are small details that produce huge impact on patient's mental well-being and post transplant follow-up compliance.
Final thoughts
Evaluating patients for transplantation is a complex process. It is not uncommon to consult on patients with clinical scenarios where high-quality data from clinical trials are not available to guide evidence-based decisions. While evaluating such patients, we must always encourage them to participate in any available clinical trials. Outside the setting of a clinical trial, after considering all the caveats discussed above, if transplantation remains an appropriate treatment option with a reasonable risk/benefit ratio in the view of treating transplant physician, then it is certainly reasonable to offer HSCT to potential candidates.
